X0306 4 2020-12-07 0001682852 Moderna, Inc. MRNA 0001690927 Zaks Tal Zvi C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Medical Officer Common Stock 2020-12-07 4 M 0 1467 12.21 A 1467 D Common Stock 2020-12-07 4 M 0 5000 14.22 A 6467 D Common Stock 2020-12-07 4 M 0 3533 12.21 A 10000 D Common Stock 2020-12-07 4 M 0 10000 19.15 A 20000 D Common Stock 2020-12-07 4 S 0 1696 153.86 D 18304 D Common Stock 2020-12-07 4 S 0 2459 154.73 D 15845 D Common Stock 2020-12-07 4 S 0 789 155.50 D 15056 D Common Stock 2020-12-07 4 S 0 1597 156.95 D 13459 D Common Stock 2020-12-07 4 S 0 4863 158.07 D 8596 D Common Stock 2020-12-07 4 S 0 2344 159.14 D 6252 D Common Stock 2020-12-07 4 S 0 528 159.75 D 5724 D Common Stock 2020-12-07 4 S 0 2619 161.65 D 3105 D Common Stock 2020-12-07 4 S 0 2962 162.64 D 143 D Common Stock 2020-12-07 4 S 0 143 163.49 D 0 D Stock Option (Right to Buy) 12.21 2020-12-07 4 M 0 1467 0 D 2027-02-23 Common Stock 1467 11478 D Stock Option (Right to Buy) 14.22 2020-12-07 4 M 0 5000 0 D 2028-02-28 Common Stock 5000 50209 D Stock Option (Right to Buy) 12.21 2020-12-07 4 M 0 3533 0 D 2027-10-03 Common Stock 3533 202291 D Stock Option (Right to Buy) 19.15 2020-12-07 4 M 0 10000 0 D 2026-08-10 Common Stock 10000 14790 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.24 to $154.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.25 to $155.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.26 to $156.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.51 to $157.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.60 to $158.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.65 to $159.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.66 to $160.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.05 to $162.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.17 to $163.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.37 to $163.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). This option is fully vested and exercisable. /s/ Lori Henderson, as Attorney-in-Fact 2020-12-09